Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alprostadil liposomal
- Development stage
- Phase 2
- Lead developer
- CSPC ZhongQi Pharmaceutical Technology
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**Alprostadil liposomal** is a liposomal formulation of alprostadil, a synthetic analog of prostaglandin E1 (PGE1), designed to enhance delivery and reduce side effects compared to standard alprostadil injections. It acts as a **vasodilator** by binding to EP receptors, activating adenylate cyclase, increasing cAMP levels, relaxing smooth muscle, inhibiting platelet aggregation, and exhibiting anti-inflammatory and cytoprotective effects. Primarily investigated for **atherosclerotic occlusive disease of the lower extremities** (e.g., improving claudication distance), **prevention of contrast-induced acute kidney injury (CI-AKI)** in PCI patients, and other vascular/ischemic conditions; developed by Chinese firms like CSPC ZhongQi, administered intravenously.[3][6][13]
- Brand names
- Liprostin
- Other names
- alprostadil liposomes for injectionalprostadil liposome for injectionLipo-PGE1Lipo-PGE-1Lipo-PGE 1
02
Targets
PTGIR (Prostanoid IP Receptor)PTGER1 (Prostaglandin E Receptor 1)PTGER2 (Prostaglandin E2 receptor EP2)PTGER3 (Prostaglandin E2 receptor EP3 subtype)PTGER4 (Prostaglandin E2 receptor EP4 subtype)
Beyond the preview
Go deeper on alprostadil liposomal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alprostadil liposomal.